ERBB3 and breast cancer: miR-148a attenuates angiogenesis likely through directly inhibiting ERBB3 for transmitting the signals to its downstream signaling molecules.Our findings suggest that miR-148a/ERBB3 pathway would be a promising therapeutic target for breast cancer in the future.